… reboxetine. Back in June 2025, the US Food and Drug Administration (FDA … of this important investigational medicine for the approximately … , in the completed trials.”2 Fibromyalgia, which is … prevalence and impact, current treatment options remain limited. …

… initiated the FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for … the SS-enantiomer of racemic reboxetine. AXS-14 remains investigational and … yet approved by the FDA. Axsome develops treatments targeting central nervous system …

… multicenter, randomized withdrawal trial in patients with … reboxetine. AXS-14 is an investigational drug product not approved by the FDA … clinical trials and anticipated clinical trials for … . Treatment Patterns Associated with ACR-Recommended Medications in …

… narcolepsy. AXS-12 (reboxetine) is a highly selective … efficacy trials, and a completed long-term safety trial. … and Drug Administration (FDA) Orphan Drug Designation for the treatment of … American Academy of Sleep Medicine. The International Classification …

… Medical University, Luzhou, China, and colleagues. "Therefore, incorporating antidepressants into future treatment … , placebo-controlled trials, comprising 655 … escitalopram (n=1), reboxetine (n=3), citalopram … extrapyramidal or sedative drug side effects. …

… & Drug Administration (FDA) website from … controlled trials (RCTs) comparing antidepressants … , doxepin, levomilnacipran, reboxetine, desvenlafaxine, venlafaxine, and … Antidepressant monotherapy: A claims database analysis of treatment changes and treatment …

… US Food & Drug Administration (FDA) website from database … randomized controlled trials (RCTs) comparing antidepressants and placebo … antidepressants with placebo. RCTs had a median treatment duration … ), phenelzine (n=1), reboxetine (n=5), selegiline (n …

… this important investigational medicine for the approximately … reboxetine. AXS-14 is an investigational drug product not approved by the FDA … portfolio includes FDA-approved treatments for major … clinical trials and anticipated clinical trials for …

… Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology … AXS-12 AXS-12 (reboxetine) is a highly … Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of … ongoing clinical trials and anticipated clinical trials for the …

… their primary endpoints. Both trials were conducted by Pfizer. … the FDA’s Division of Anesthesiology, Addiction Medicine and Pain Medicine … to the New York biotech’s first quarter earnings … revitalize reboxetine, called AXS-12 at Axsome, as a treatment for …